Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

98.35USD
10:34am EDT
Change (% chg)

$0.58 (+0.59%)
Prev Close
$97.77
Open
$98.86
Day's High
$99.37
Day's Low
$97.98
Volume
109,345
Avg. Vol
511,302
52-wk High
$121.75
52-wk Low
$81.13

Latest Key Developments (Source: Significant Developments)

German patent court issues initial decision
Thursday, 9 Mar 2017 06:35am EST 

Edwards Lifesciences Corp - : District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves . Edwards is not updating its 2017 financial guidance . Does not presently anticipate disruption to supply of sapien 3 valves to patients . Court also ruled Edwards Sapien 3 valve infringes two of Boston Scientific's patents for outer seals of transcatheter heart valves .Will promptly request an appeal.  Full Article

Boston Scientific receives favorable rulings in Edwards Lifesciences litigation
Thursday, 9 Mar 2017 04:59am EST 

Boston Scientific Corp : Boston scientific receives favorable rulings in edwards lifesciences litigation . German district court of Düsseldorf determined that Edwards Lifesciences infringed two patents of Boston Scientific . Edwards has stated that it will seek permission to appeal this judgment . Edwards Lifesciences and Boston Scientific can appeal each of four decisions as far as district court of Düsseldorf has decided against them .believes that '550 patent will be revoked by European patent office.  Full Article

Edwards Lifesciences says UK patent court issues decision on transcatheter heart valves
Friday, 3 Mar 2017 06:50am EST 

Edwards Lifesciences Corp : UK patent court issues initial decision . Edwards Lifesciences Corp says company is not changing its financial guidance . Edwards Lifesciences Corp - Edwards will promptly request an appeal on specific aspects of decision . Edwards Lifesciences-patents court in uk determined one of boston scientific's patents related to seals for transcatheter heart valves valve is invalid . Edwards Lifesciences Corp - court's decision does not affect commercial availability of sapien 3 valve . Edwards Lifesciences - boston scientific initiated litigation involves multiple patents in multiple venues, to yield court actions over extended period .Edwards Lifesciences Corp - patents court in uk has determined a second patent of Boston Scientific is valid and infringed.  Full Article

Edwards Lifesciences Corp Q4 EPS $0.73
Wednesday, 1 Feb 2017 04:15pm EST 

Edwards Lifesciences Corp : Q4 global transcatheter heart valve therapy sales up 29 percent to $432 million . Sees FY 2017 sales between $3.0 billion and $3.4 billion; Sees FY 2017 adjusted eps between $3.30 and $3.45 . Q4 EPS $0.73; Q4 adjusted EPS $0.75; q4 sales up 14 percent to $768 million . Sees Q1 2017 sales between $760 million and $800 million; Sees Q1 2017 adjusted EPS between $0.79 and $0.89 . Q4 earnings per share view $0.72, revenue view $759.5 million -- Thomson Reuters I/B/E/S . Fy2017 earnings per share view $3.39, revenue view $3.25 billion -- Thomson Reuters I/B/E/S .Q1 earnings per share view $0.81, revenue view $779.1 million -- Thomson Reuters I/B/E/S.  Full Article

Neovasc ordered to pay $21 million enhanced damages in patent litigation with Edwards' CardiAQ unit
Monday, 31 Oct 2016 03:33pm EDT 

: U.S. judge orders Neovasc Inc to pay $21 million enhanced damages in Edwards Lifesciences litigation--court records . U.S. district judge allison burroughs in Boston grants request for enhanced damages by edwards' cardiaq unit . Judge orders Neovasc to destroy a variety of information that cardiaq sent it between June 2009 and April 2010 . Judge denies Neovasc bid for new trial on damages and trade secrets Keywords: NEOVASC/BRIEF.  Full Article

FDA approves expanded indication for Sapien XT and Sapien 3 transcatheter heart valves
Thursday, 18 Aug 2016 02:37pm EDT 

U.S. FDA : U.S. Food and Drug Administration today approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves .Requiring Edwards to conduct post-approval study to follow patients treated with either device in first,second clinical studies for 10 years.  Full Article

EDWARDS INTUITY Elite Rapid Deployment Valve receives FDA approval
Monday, 15 Aug 2016 08:30am EDT 

Edwards Lifesciences Corp :Edwards INTUITY Elite Rapid Deployment Valve receives FDA approval.  Full Article

Edwards Lifesciences Q2 Adjusted EPS $0.76
Tuesday, 26 Jul 2016 04:15pm EDT 

Edwards Lifesciences Corp : Sees Q3 Sales Between $720 Mln - $760 Mln; Sees Q3 Adjusted Earnings Per Share Between $0.62 - $0.68 . Q3 Earnings Per Share View $0.64, Revenue View $708.1 Million; Fy2016 Earnings Per Share View $2.76, Revenue View $2.89 Billion -- Thomson Reuters I/B/E/S . Q2 Transcatheter Heart Valve Therapy Sales Of $418.6 Million, Up 48.7 Percent From Previous Year . Edwards Lifesciences Corp Q2 Earnings Per Share $0.58, Q2 Adjusted Earnings Per Share $0.76; Q2 Sales $759.3 Million, Up 23.1 Percent From Previous Year . Sees 2016 Total Sales At High End Of $2.7 Billion-$3.0 Billion; Sees 2016 Adjusted Earnings Per Share $2.78 - $2.88 .Q2 Earnings Per Share View $0.70, Revenue View $724.3 Million -- Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences says jury returns verdict in favor of CardiAQ in case with Neovasc
Thursday, 19 May 2016 07:47pm EDT 

Edwards Lifesciences Corp : Federal jury in Boston returned a verdict in favor of CardiAQ in lawsuit filed against a former service provider, Neovasc . Jury awarded damages of $70 million for trade secret misappropriation ."Jury found that Neovasc breached non-disclosure agreement between parties, misappropriated CardiAQ's trade secrets".  Full Article

Edwards Lifesciences Corp gives Q4 2015 guidance in line with analysts' estimates; reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Monday, 26 Oct 2015 04:15pm EDT 

Edwards Lifesciences Corp:Continues to expect FY 2015 total sales to be between $2.3 billion to $2.5 billion.Increases its guidance for FY 2015 diluted earnings per share, excluding special items, to a range of $4.43 to $4.53, from its previous range of $4.30 to $4.40.Says for Q4 2015, at current foreign exchange rates, the company projects total sales to be between $620 million and $660 million, and diluted earnings per share, excluding special items, to be between $1.11 and $1.21.Q4 2015 revenue of $631 million and EPS of $1.14 - Thomson Reuters I/B/E/S.FY 2015 revenue of $2.44 billion and EPS of $4.37 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-German patent court issues initial decision

* District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves